Old drug, new clinical use, no man's land for the indication: an awareness call from European experts
ESMO Open
.
2020;5(1):e000615.
doi: 10.1136/esmoopen-2019-000615.
Epub 2020 Sep 30.
Authors
Stefan Rauh
1
,
Leonidas Mavroeidis
2
,
Panagiotis Ntellas
2
,
Ioanna Gazouli
2
,
Stefania Gkoura
2
,
Alexandra Papadaki
3
,
Davide Mauri
2
,
Yannis Metaxas
4
,
Jean-Yves Douillard
5
,
George Pentheroudakis
2
Affiliations
1
Department of Hemato Oncology, Centre Hospitalier Emile Mayrisch, Esch, Luxembourg. Electronic address:
[email protected]
.
2
Department of Medical Oncology, University of Ioannina School of Medicine, Ioannina, Greece.
3
Society of Study of Clonal Heterogeneity of Neoplasia EMEKEN, Ioannina, Greece.
4
Oncology/Hematology, Kantonsspital Graubunden, Chur, Graubünden, Switzerland.
5
European Society for Medical Oncology, Viganello, Switzerland.
PMID:
33551069
PMCID:
PMC7046389
DOI:
10.1136/esmoopen-2019-000615
No abstract available
Keywords:
EMA application process; off licence indication; old drug new indication; reimbursement.
Publication types
Editorial
MeSH terms
Finger Injuries
Humans
Pharmaceutical Preparations*
Tendon Injuries
Substances
Pharmaceutical Preparations